All News
PALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.
Read Article
Methotrexate Nonadherence is Common
Researchers from Belgium studied patient adherence to MTX (given orally or via injection) in 129 rheumatoid arthritis (RA) patients over a 16-week period using an electronic monitoring system and two validated adherence questionnaires.
Read Article
FDA Approves Cosentyx for Ankylosing Spondylitis and Psoriatic Arthritis
Cosentyx (secukinumab) was approved by the FDA on 15 January, 2016 for patients with active ankyosing spondylitis (AS) and psoriatic arthritis (PsA).
Read Article
Game-Changers 2015: Refining Treatment in Arthritis
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPa
Read Article
The Global Prevalence of Spondyloarthritis
SpA is a common disease, but with large variation in reported prevalence estimates, partly explained by differences in demographical and methodological characteristics.
Read Article
Secukinumab Shows Efficacy in Two Ankylosing Spondylitis Trials
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis.
Read Article
Increased Adverse Pregnancy Outcomes in Ankylosing Spondylitis
Although ankylosing spondylitis affects a predominantly male population, the ratio of men to women has declined from 9-10:1 in earlier studies to more recent estimates of 2-3:1 (F:M).
Read Article
Tofacitinib Shows Promise in Alopecia, Eczema and Vitiligo
Tofacitinib has been approved for use in rheumatoid arthritis.
Read Article
DSB: Managing Methotrexate Toxicity (Best of 2015: #1)
Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA.
Read Article
How I Choose Biologics (Best of 2015)
Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.
Read Article
Alcohol and Methotrexate - What Do You Advise? (Best of 2015: #9)
What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX?
Read Article
RA Guidelines, Methotrexate and Mortal Risks in Gout: November 2015 top social media news
Here's what you may have missed: in November 2015, RheumNow published 80 tweets on news, research and teaching points that impact the rheumatology community. We had a reach (impressions) of 79,100, 79 mentions, and over 3399 visits to RheumNow.com to check out what we publish.
Read Article
EULAR 2015 Psoriatic Arthritis Treatment Guidelines
The management of psoriatic disease, including psoriatic arthritis (PsA) has evolved significantly in the last decade. Nevertheless, there are still some uncertainties - such as what the role of methotrexate should be, and when to use newer and novel therapies.
Read Article
The Rising Price of Dermatologic Drugs
Containment of health care costs was a primary goal of the Patient Protection and Affordable Care Act. But there is little evidence of success in curbing the rising price of prescription drugs. As such, many medications are unaffordable to those who need them.
Read Article
Interstitial Lung Disease Not Increased with Biologics
Extraarticular manifestations affect more then half of rheumatoid arthritis (RA) patients, and interstitial lung disease or "RA lung" is one of the more prevalent. The frequency of ILD in patients with RA varies from 5% to 58%.
Read Article
From Psoriasis to PsA: Who and Why?
The number of patients with psoriasis who go on to develop psoriatic arthritis (PsA) is considerably higher than has previously been estimated, a prospective cohort study found.
Read Article
Psoriasis May Not Be a Risk for CV Events
Patients with psoriatic skin and joint disease are uniquely susceptible to multiple comorbidities, obesity and possibly more cardiovascular risks. In rheumatoid arthritis, the increased CV risk and CV events have been closely aligned with inflammation and disease activity.
Read Article
SB4 - A Second Biosimilar Up For Review in Europe
A biosimilar of etanercept (Enbrel) made by the South Korean company Samsung Bioepis is under consideration by regulators in the European Union. Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim with its version of etanercept.
Read Article
Alcohol and Methotrexate - What Do You Advise?
What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX?
Read Article
Are Guidelines Worth the Cost?
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
